Anurag Singh, PhD
Assistant Professor
Boston University School of Medicine
Dept of Pharmacology & Experimental Therapeutics

PhD, University of North Carolina at Chapel Hill

Dr. Singh has expertise in cancer biology, functional genomics and cancer pharmacology. His laboratory studies deregulated signal transduction networks that contribute to the pathophysiology of lung, pancreatic and colon cancers. Adenocarcinomas that arise in these tissues frequently harbor mutations in the KRAS oncogene or components of the KRAS signaling pathway, such as BRAF or PI3K. The core KRAS signaling pathway has been very well characterized but the precise mechanisms governing tumor maintenance in KRAS mutant cancers remain to be fully elucidated. Through comparative whole genome expression profiling, Dr. Singh has previously shown that KRAS mutant cancers can be classified into discrete molecular subtypes based on a phenotypic dichotomy of KRAS oncogene “addiction” or dependency. He derived tissue or lineage-specific KRAS dependency gene expression signatures that reflect differing modes of KRAS-mediated signal transduction in lung versus pancreatic versus colon cancers. Therefore, Dr. Singh hypothesizes that context-specificity is critical in the analysis of KRAS signaling networks.

Current research in the Singh lab is focused on delineating mechanisms of oncogene dependency in a broader context. Preliminary results indicate that triple-negative breast cancer (TNBC) cells are KRAS-dependent. Based on this, TNBC KRAS dependency signatures will be derived to reveal candidate therapeutic targets for TNBC treatment. In melanoma, the NRAS oncogene (related to KRAS) is mutated in 20-30% of cases. NRAS dependency in melanoma is strongly correlated with expression and activation of the melanocyte lineage transcription factor and oncogene, MITF. Efforts are underway to understand MITF-mediated transcriptional mechanisms that control NRAS-dependency, with the overarching goal of identifying combination therapeutic approaches to treat NRAS mutant melenoma.

Assistant Professor
Boston University School of Medicine
Hematology & Medical Oncology

Boston University
BU-BMC Cancer Center

Boston University
Genome Science Institute

Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Graduate Medical Sciences

2017-2018 Boston University School of Medicine: Dahod Breast Cancer Research Award
2015-2018 Melanoma Research Alliance: Young Investigator Award
2013-2014 American Cancer Society: Institutional Research Grant, Pilot Award
2013-2014 American Lung Association: Lung Cancer Discovery Award
2010-2015 NIH/NCI: Howard Temin Award/K99/R00

Co-targeting PAK kinase and Bcl family proteins in NRAS dependent melanoma
12/01/2018 - 11/30/2020 (PI)
American Association for Cancer Research

Molecular determinants of NRAS oncogene dependency in melanoma
05/01/2015 - 10/30/2018 (PI)
Melanoma Research Alliance

Defining lineage-specific determinants of K-Ras addiction in human cancers
06/01/2012 - 05/31/2016 (PI)
NIH/National Cancer Institute

Identifying a KRAS Regulated Micro-RNA Signaling Network in Lung Cancer
07/01/2013 - 12/31/2015 (PI)
American Lung Association

Institutional Research Grant
01/01/2012 - 12/31/2015 (PI of Sub-Project / SP)
PI: Avrum Spira, MD
American Cancer Society - MA Division


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Mehta AK, Hua K, Whipple W, Nguyen MT, Liu CT, Haybaeck J, Weidhaas J, Settleman J, Singh A. Regulation of autophagy, NF-?B signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells. Sci Signal. 2017 Sep 12; 10(496).View Related Profiles. PMID: 28900044; DOI: 10.1126/scisignal.aam6291;
  2. Grant TJ, Mehta AK, Gupta A, Sharif AAD, Arora KS, Deshpande V, Ting DT, Bardeesy N, Ganem NJ, Hergovich A, Singh A. STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. Oncotarget. 2017 Oct 03; 8(45):78556-78572.View Related Profiles. PMID: 29108249
  3. Grant TJ, Hua K, Singh A. Molecular Pathogenesis of Pancreatic Cancer. Prog Mol Biol Transl Sci. 2016; 144:241-275.View Related Profiles. PMID: 27865459; DOI: 10.1016/bs.pmbts.2016.09.008;
  4. McNew KL, Whipple WJ, Mehta AK, Grant TJ, Ray L, Kenny C, Singh A. MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling. Mol Cancer Res. 2016 Dec; 14(12):1204-1216.View Related Profiles. PMID: 27655129
  5. Anderson NM, Li D, Peng HL, Laroche FJ, Mansour MR, Gjini E, Aioub M, Helman DJ, Roderick JE, Cheng T, Harrold I, Samaha Y, Meng L, Amsterdam A, Neuberg DS, Denton TT, Sanda T, Kelliher MA, Singh A, Look AT, Feng H. The TCA cycle transferase DLST is important for MYC-mediated leukemogenesis. Leukemia. 2016 Jun; 30(6):1365-74.View Related Profiles. PMID: 26876595; PMCID: PMC4889531; DOI: 10.1038/leu.2016.26;
  6. Grant, T., Hua, K., Singh A. Progress in Molecular Biology and Translational Science. Molecular Pathogenesis of Pancreatic Cancer. Elsevier Press. 2016; 144:214-275.
  7. Anurag Singh. Systems biology of cancer. Chapter 27. Deregulated signaling networks in lung cancer. Cambridge University Press. Cambridge UK. 2015; N/A(N/A):421-443.
  8. Javaid S, Zhang J, Smolen GA, Yu M, Wittner BS, Singh A, Arora KS, Madden MW, Desai R, Zubrowski MJ, Schott BJ, Ting DT, Stott SL, Toner M, Maheswaran S, Shioda T, Ramaswamy S, Haber DA. MAPK7 Regulates EMT Features and Modulates the Generation of CTCs. Mol Cancer Res. 2015 May; 13(5):934-43. PMID: 25678598; PMCID: PMC4433453; DOI: 10.1158/1541-7786.MCR-14-0604;
  9. Wang M, Kern AM, Hülskötter M, Greninger P, Singh A, Pan Y, Chowdhury D, Krause M, Baumann M, Benes CH, Efstathiou JA, Settleman J, Willers H. EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation. Cancer Res. 2014 May 15; 74(10):2825-34. PMID: 24648348; DOI: 10.1158/0008-5472.CAN-13-3157;
  10. Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, Song Y, Lifshits E, Hung KE, Shioda T, Dias-Santagata D, Singh A, Settleman J, Benes CH, Mino-Kenudson M, Wong KK, Engelman JA. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell. 2013 Jan 14; 23(1):121-8. PMID: 23245996; PMCID: PMC3667614; DOI: 10.1016/j.ccr.2012.11.007;
Showing 10 of 22 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 22 publications over 12 distinct years, with a maximum of 4 publications in 2016


In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Colon cancer
Lung cancer
Pancreatic cancer
Signal Transduction Pathways
Gastrointestinal Cancer

Available to Mentor as: (Review Mentor Role Definitions):
  • Co-Mentor or Peer Mentor
  • Education Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:

72 E. Concord St Silvio Conte (K)
Boston MA 02118
Google Map

Singh's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department